Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: MTAC), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.
MedTech Acquisition Corporation (MTAC), a specialized SPAC targeting transformative medical technology companies, provides investors and industry observers with critical updates through this centralized news hub. Track merger developments, partnership announcements, and strategic moves within the dynamic healthcare innovation sector.
This resource delivers timely updates on MTAC's progress in identifying acquisition targets across medical devices, diagnostics, and digital health. Users gain insights into the company's evaluation criteria for potential mergers and its role in bringing emerging technologies to public markets.
The page aggregates official announcements regarding financial positioning, leadership insights, and sector-specific developments. Recent coverage includes MTAC's engagement with therapeutic innovators like TriSalus Life Sciences, reflecting its focus on clinically impactful technologies.
Bookmark this page for streamlined access to MTAC's evolving story as it shapes the future of medical technology through strategic acquisitions. Check back regularly for verified updates directly impacting the healthcare investment landscape.
Memic Innovative Surgery Ltd. announced the acquisition of its Hominis® Surgical System by three leading hospitals in the U.S. The system, designed for minimally invasive gynecological procedures, offers enhanced capabilities with its unique humanoid-shaped robotic arms. The adoption by Kendall Regional Medical Center, AdventHealth Celebration, and The Women's Hospital at Jackson Memorial signifies a crucial step in market expansion. The Hominis system, which received FDA authorization in February 2021, allows for transvaginal approaches, promising reduced pain and faster recovery for patients.
Memic Innovative Surgery has announced the appointment of Robert L. Ryan and Sandra Morgan to its board of directors, pending the completion of its business combination with MedTech Acquisition Corporation (MTAC), expected in Q4 2021. Ryan, former CFO of Medtronic, and Morgan, ex-senior VP at HCA, bring extensive experience in healthcare and technology sectors. This leadership addition aims to enhance Memic's strategic direction and commercial expansion of its Hominis platform, which offers innovative robotic surgical solutions.
Peregrine Ventures' portfolio company, Memic Innovative Surgery Ltd., has agreed to a business combination with MedTech Acquisition Corporation (NASDAQ: MTAC), a SPAC focused on medical technology. The merger is set to complete in Q4 2021, estimating a pro-forma equity value exceeding $1 billion. Memic's Hominis® robotic platform, the first FDA-authorized surgical robot with humanoid-shaped arms, tackles surgical challenges in women's health, particularly hysterectomies. Additionally, Memic plans to apply for CE Mark approval in the EU and expand into general surgery indications.
Memic Innovative Surgery and MedTech Acquisition Corporation (MTAC) are set to merge, creating a combined entity valued at over $1 billion. The merger is expected to complete in Q4 2021, with Memic’s innovative Hominis surgical robot being central to their strategy. The Hominis platform, FDA-authorized for certain surgeries, aims to enhance minimally invasive procedures in women's health. The combined company will maintain approximately $360 million in cash, and existing Memic shareholders will roll their equity into the new entity.
MedTech Acquisition Corporation (Nasdaq: MTACU) announced it received a notice from Nasdaq due to the late filing of its Quarterly Report on Form 10-Q for Q1 2021. The company failed to meet the deadline because of accounting issues regarding outstanding warrants. Nasdaq has granted the company 60 days, until July 26, 2021, to submit a compliance plan. If accepted, an extension of up to 180 days may be granted. Failure to comply could lead to suspension or delisting, negatively impacting the trading of its units, warrants, and common stock.
MedTech Acquisition Corporation (Nasdaq:MTACU) announced that from February 8, 2021, holders of its 25 million initial public offering units can trade shares of Class A common stock and warrants separately on Nasdaq. The shares will trade under the symbols 'MTAC' for common stock and 'MTACW' for warrants, while the undivided units will continue trading as 'MTACU.' The registration statement for these securities was declared effective by the SEC on December 17, 2020. MedTech Acquisition aims to focus on merging with businesses in the medical technology sector.
MedTech Acquisition Corporation closed its initial public offering of 25,000,000 units, including 3,000,000 units from the underwriters’ over-allotment, at $10.00 per unit, totaling $250,000,000 in gross proceeds. The units commenced trading on Nasdaq under the symbol MTACU on December 18, 2020. Each unit comprises one share of Class A common stock and one-third of a redeemable warrant. Funds raised are placed in a trust account for future business combinations, primarily focusing on the medical technology sector.
MedTech Acquisition Corporation announced the pricing of its initial public offering (IPO) of 22,000,000 units at $10.00 each, scheduled to trade on Nasdaq under the symbol MTACU starting December 18, 2020. Each unit consists of one share of Class A common stock and one-third of a redeemable warrant, which can be exercised at $11.50 per share. The company, a blank check entity, aims to pursue a business combination in the medical technology sector. Raymond James & Associates is the sole book-running manager for the offering, with a 45-day option for underwriters for an additional 3,300,000 units.
FAQ
What is the market cap of MedTech Acquisition Corporation (MTAC)?
